

Imugene Ltd

22:34 22 Oct 2019

Imugene welcomes receipt of US Department of Defense grant for City of Hope cancer researchers

Imugene Limited (ASX:IMU) has revealed that City of Hope researchers Yanghee Woo, MD and Yuman Fong, MD have received a \$564,173 US Department of Defense Grant for the oncolytic virotherapy CF33 in gastric cancer.

Background

The CF33 oncolytic virus was developed at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in California.

Imugene's proposal to license CF33 from City of Hope is awaiting satisfaction of customary conditions precedent and shareholder approval at the Extraordinary General Meeting (EGM) to be held on November 18, 2019.

Focus on gastric cancer

The grant focuses on the area of stomach (gastric) cancer (GC), a disease that disproportionately affects US military service members, veterans, and their beneficiaries who have increased exposure to hazardous environmental risk factors, such as H. pylori, Epstein-Barr viral infections, radiation, and tobacco smoking.

Peritoneal carcinomatosis (PC) is a fatal evolution of GC for which there is no effective treatment.

Across military families and the general population, over 60% of all patients with GC will develop peritoneal disease as the most common manifestation of recurrence or metastatic presentation.

The progression of primary GC to PC is facilitated by the unique peritoneal tumour microenvironment, where metastatic peritoneal seeding requires evasion of anti-tumour immunity and maintenance of a highly immunosuppressive microenvironment.

The researchers rationalize that a combined approach using Imugene's proposed license for novel oncolytic virus CF33 armed to express an anti-PD-L1 antibody as immune modulator could specifically kill cancer cells, convert the immunologically 'cold' environment of PC into a 'hot' environment, and enhance the overall efficacy of GC therapy.

Expanding CF33 development

Imugene managing director and CEO Leslie Chong said: "Imugene and City of Hope are committed to help improve the length and quality of life for patients

Price: 0.033

Market Cap: \$146.06 m

1 Year Share Price Graph



July 2019 December 2019 June 2020

Share Information

Code: IMU

Listing: ASX

52 week High Low
0.063 0.014

Sector: Pharma & Biotech

Website: www.imugene.com

Company Synopsis:

Imugene Ltd (ASX:IMU) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com

with gastric cancer.

"We congratulate Dr Yanghee Woo and Dr Yuman Fong on receiving this sizable grant.

"It is an honour to work with the prestigious and prolific team at City of Hope to expand the development of CF33".

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).